Back to results
US 2020/0369739 A1Published application
Single-chain tnf receptor 2 agonist fusion proteins
AssigneeRelinia, Inc.
InventorsDavid C Foster, Lutz B Giebel, Leonard G Presta
Life of this patent
Estimating the term…
Abstract
This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
Claims32
A fusion protein comprising:
- a. a first TNF homology domain (THD) comprising D143N/A145R mutations, wherein the THD has at least 95% identity to SEQ ID NO:
- 3;
- b. a second THD comprising D143N/A145R mutations, wherein the THD has at least 95% identity to SEQ ID NO:
- 3;
- c. a third THD comprising D143N/A145R mutations, wherein the THD has at least 95% identity to SEQ ID NO:
- 3;
- d. a single immunoglobulin Fc domain;
- and
- e. a first linker peptide covalently linking the first and second THDs and a second linker covalently linking the second and third THDs.
6 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.